Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation

Gregory A. Abel, Randy Albelda, Nandita D Khera, Theresa Hahn, Diana Y. Salas Coronado, Oreofe O. Odejide, Kira Bona, Reginald Tucker-Seeley, Robert Soiffer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Although hematopoietic cell transplantation (HCT) is the only curative therapy for many advanced hematologic cancers, little is known about the financial hardship experienced by HCT patients nor the association of hardship with patient-reported outcomes. We mailed a 43-item survey to adult patients approximately 180 days after their first autologous or allogeneic HCT at 3 high-volume centers. We assessed decreases in household income; difficulty with HCT-related costs, such as need to relocate or travel; and 2 types of hardship: hardship_1 (reporting 1 or 2 of the following: dissatisfaction with present finances, difficulty meeting monthly bill payments, or not having enough money at the end of the month) and “hardship_2” (reporting all 3). Patient-reported stress was measured with the Perceived Stress Scale-4, and 7-point scales were provided for perceptions of overall quality of life (QOL) and health. In total, 325 of 499 surveys (65.1%) were received. The median days since HCT was 173; 47% underwent an allogeneic HCT, 60% were male, 51% were > 60 years old, and 92% were white. Overall, 46% reported income decline after HCT, 56% reported hardship_1, and 15% reported hardship_2. In multivariable models controlling for income, those reporting difficulty paying for HCT-related costs were more likely to report financial hardship (odds ratio, 6.9; 95% confidence interval, 3.8 to 12.3). Hardship_1 was associated with QOL below the median (odds ratio, 2.9; 95% confidence interval, 1.7 to 4.9), health status below the median (odds ratio, 2.2; 95% confidence interval, 1.3 to 3.6), and stress above the median (odds ratio, 2.1; 95% confidence interval, 1.3 to 3.5). In this sizable cohort of HCT patients, financial hardship was prevalent and associated with worse QOL and higher levels of perceived stress. Interventions to address patient financial hardship—especially those that ameliorate HCT-specific costs—are likely to improve patient-reported outcomes.

Original languageEnglish (US)
Pages (from-to)1504-1510
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Cell Transplantation
Odds Ratio
Confidence Intervals
Quality of Life
Patient Reported Outcome Measures
Costs and Cost Analysis
Health Status

Keywords

  • Financial hardship
  • Health-related quality of life
  • Perceived stress
  • Stem cell transplantation

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Transplantation

Cite this

Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. / Abel, Gregory A.; Albelda, Randy; Khera, Nandita D; Hahn, Theresa; Salas Coronado, Diana Y.; Odejide, Oreofe O.; Bona, Kira; Tucker-Seeley, Reginald; Soiffer, Robert.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 8, 01.08.2016, p. 1504-1510.

Research output: Contribution to journalArticle

Abel, GA, Albelda, R, Khera, ND, Hahn, T, Salas Coronado, DY, Odejide, OO, Bona, K, Tucker-Seeley, R & Soiffer, R 2016, 'Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 22, no. 8, pp. 1504-1510. https://doi.org/10.1016/j.bbmt.2016.05.008
Abel, Gregory A. ; Albelda, Randy ; Khera, Nandita D ; Hahn, Theresa ; Salas Coronado, Diana Y. ; Odejide, Oreofe O. ; Bona, Kira ; Tucker-Seeley, Reginald ; Soiffer, Robert. / Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2016 ; Vol. 22, No. 8. pp. 1504-1510.
@article{e875808f9c9a4d86bef134575d078d28,
title = "Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation",
abstract = "Although hematopoietic cell transplantation (HCT) is the only curative therapy for many advanced hematologic cancers, little is known about the financial hardship experienced by HCT patients nor the association of hardship with patient-reported outcomes. We mailed a 43-item survey to adult patients approximately 180 days after their first autologous or allogeneic HCT at 3 high-volume centers. We assessed decreases in household income; difficulty with HCT-related costs, such as need to relocate or travel; and 2 types of hardship: hardship_1 (reporting 1 or 2 of the following: dissatisfaction with present finances, difficulty meeting monthly bill payments, or not having enough money at the end of the month) and “hardship_2” (reporting all 3). Patient-reported stress was measured with the Perceived Stress Scale-4, and 7-point scales were provided for perceptions of overall quality of life (QOL) and health. In total, 325 of 499 surveys (65.1{\%}) were received. The median days since HCT was 173; 47{\%} underwent an allogeneic HCT, 60{\%} were male, 51{\%} were > 60 years old, and 92{\%} were white. Overall, 46{\%} reported income decline after HCT, 56{\%} reported hardship_1, and 15{\%} reported hardship_2. In multivariable models controlling for income, those reporting difficulty paying for HCT-related costs were more likely to report financial hardship (odds ratio, 6.9; 95{\%} confidence interval, 3.8 to 12.3). Hardship_1 was associated with QOL below the median (odds ratio, 2.9; 95{\%} confidence interval, 1.7 to 4.9), health status below the median (odds ratio, 2.2; 95{\%} confidence interval, 1.3 to 3.6), and stress above the median (odds ratio, 2.1; 95{\%} confidence interval, 1.3 to 3.5). In this sizable cohort of HCT patients, financial hardship was prevalent and associated with worse QOL and higher levels of perceived stress. Interventions to address patient financial hardship—especially those that ameliorate HCT-specific costs—are likely to improve patient-reported outcomes.",
keywords = "Financial hardship, Health-related quality of life, Perceived stress, Stem cell transplantation",
author = "Abel, {Gregory A.} and Randy Albelda and Khera, {Nandita D} and Theresa Hahn and {Salas Coronado}, {Diana Y.} and Odejide, {Oreofe O.} and Kira Bona and Reginald Tucker-Seeley and Robert Soiffer",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2016.05.008",
language = "English (US)",
volume = "22",
pages = "1504--1510",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation

AU - Abel, Gregory A.

AU - Albelda, Randy

AU - Khera, Nandita D

AU - Hahn, Theresa

AU - Salas Coronado, Diana Y.

AU - Odejide, Oreofe O.

AU - Bona, Kira

AU - Tucker-Seeley, Reginald

AU - Soiffer, Robert

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Although hematopoietic cell transplantation (HCT) is the only curative therapy for many advanced hematologic cancers, little is known about the financial hardship experienced by HCT patients nor the association of hardship with patient-reported outcomes. We mailed a 43-item survey to adult patients approximately 180 days after their first autologous or allogeneic HCT at 3 high-volume centers. We assessed decreases in household income; difficulty with HCT-related costs, such as need to relocate or travel; and 2 types of hardship: hardship_1 (reporting 1 or 2 of the following: dissatisfaction with present finances, difficulty meeting monthly bill payments, or not having enough money at the end of the month) and “hardship_2” (reporting all 3). Patient-reported stress was measured with the Perceived Stress Scale-4, and 7-point scales were provided for perceptions of overall quality of life (QOL) and health. In total, 325 of 499 surveys (65.1%) were received. The median days since HCT was 173; 47% underwent an allogeneic HCT, 60% were male, 51% were > 60 years old, and 92% were white. Overall, 46% reported income decline after HCT, 56% reported hardship_1, and 15% reported hardship_2. In multivariable models controlling for income, those reporting difficulty paying for HCT-related costs were more likely to report financial hardship (odds ratio, 6.9; 95% confidence interval, 3.8 to 12.3). Hardship_1 was associated with QOL below the median (odds ratio, 2.9; 95% confidence interval, 1.7 to 4.9), health status below the median (odds ratio, 2.2; 95% confidence interval, 1.3 to 3.6), and stress above the median (odds ratio, 2.1; 95% confidence interval, 1.3 to 3.5). In this sizable cohort of HCT patients, financial hardship was prevalent and associated with worse QOL and higher levels of perceived stress. Interventions to address patient financial hardship—especially those that ameliorate HCT-specific costs—are likely to improve patient-reported outcomes.

AB - Although hematopoietic cell transplantation (HCT) is the only curative therapy for many advanced hematologic cancers, little is known about the financial hardship experienced by HCT patients nor the association of hardship with patient-reported outcomes. We mailed a 43-item survey to adult patients approximately 180 days after their first autologous or allogeneic HCT at 3 high-volume centers. We assessed decreases in household income; difficulty with HCT-related costs, such as need to relocate or travel; and 2 types of hardship: hardship_1 (reporting 1 or 2 of the following: dissatisfaction with present finances, difficulty meeting monthly bill payments, or not having enough money at the end of the month) and “hardship_2” (reporting all 3). Patient-reported stress was measured with the Perceived Stress Scale-4, and 7-point scales were provided for perceptions of overall quality of life (QOL) and health. In total, 325 of 499 surveys (65.1%) were received. The median days since HCT was 173; 47% underwent an allogeneic HCT, 60% were male, 51% were > 60 years old, and 92% were white. Overall, 46% reported income decline after HCT, 56% reported hardship_1, and 15% reported hardship_2. In multivariable models controlling for income, those reporting difficulty paying for HCT-related costs were more likely to report financial hardship (odds ratio, 6.9; 95% confidence interval, 3.8 to 12.3). Hardship_1 was associated with QOL below the median (odds ratio, 2.9; 95% confidence interval, 1.7 to 4.9), health status below the median (odds ratio, 2.2; 95% confidence interval, 1.3 to 3.6), and stress above the median (odds ratio, 2.1; 95% confidence interval, 1.3 to 3.5). In this sizable cohort of HCT patients, financial hardship was prevalent and associated with worse QOL and higher levels of perceived stress. Interventions to address patient financial hardship—especially those that ameliorate HCT-specific costs—are likely to improve patient-reported outcomes.

KW - Financial hardship

KW - Health-related quality of life

KW - Perceived stress

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84981320859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981320859&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.05.008

DO - 10.1016/j.bbmt.2016.05.008

M3 - Article

VL - 22

SP - 1504

EP - 1510

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -